<DOC>
	<DOCNO>NCT02392520</DOCNO>
	<brief_summary>The study aim compare novel method GnRH antagonist administration luteal phase versus conventional treatment IVF patient develop severe early ovarian hyperstimulation syndrome embryo cryopreserved .</brief_summary>
	<brief_title>Luteal Antagonist Versus Conventional Treatment Women With Severe Early Ovarian Hyperstimulation Syndrome ( OHSS )</brief_title>
	<detailed_description>GnRH antagonist administration luteal phase propose strategy treatment establish severe early OHSS , cause rapid regression syndrome outpatient basis . The approach describe tertiary OHSS prevention , thereby complement primary prevention ( GnRH antagonist protocol ) secondary prevention ( GnRH agonist trigger ) constitute OHSS-free clinic concept . No randomized control trial ( RCT ) exist date comparing luteal GnRH antagonist administration versus conventional treatment . The aim present study compare novel method GnRH antagonist administration luteal phase versus conventional treatment primary outcome time severe OHSS regression , IVF patient develop severe early OHSS embryo cryopreserved .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
	<mesh_term>Cetrorelix</mesh_term>
	<criteria>Women establish severe early OHSS . Criteria diagnosis severe OHSS require : presence moderate ( high ) ascites least two follow : enlarged ovary ( &gt; 100 mm maximal diameter ) , haematocrit ( Ht ) &gt; 45 % , white blood cell count ( WBC ) &gt; 15,000/mm3 . Women fulfil criterion</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>severe OHSS</keyword>
	<keyword>antagonist administration</keyword>
	<keyword>conventional treatment</keyword>
</DOC>